Rein Therapeutics RNTX
NASDAQ RNTX
$0.62 +0.03 (+4.99%)
At close: Oct 21, 2026 · 4:00 PM EDT

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2016 - 2025)

Updated

Rein Therapeutics (RNTX) recorded Total Non-Current Liabilities of $7.24 million in Q4 2025, down 3.7% from $7.52 million a year earlier and down 3.7% from the prior quarter.

Analysis

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends

Starting with Q4 2016, Rein Therapeutics' Total Non-Current Liabilities history includes 7 quarters.

  • Across earlier years, Total Non-Current Liabilities came in at $7.52 million in FY2024.
  • Per Business Quant, the preceding three quarters came in at $7.52 million (Q3 2025), $9.47 million (Q2 2025) and $7.75 million (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 105.50 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 106.45 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.91 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 35.10 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 97.04 Bn
10 Rein Therapeutics 42.04 Mn -1.59 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 7.24 Mn
Sep 30, 2025 7.52 Mn
Jun 30, 2025 9.47 Mn
Mar 31, 2025 7.75 Mn
Dec 31, 2024 7.52 Mn
Jun 30, 2024 8.26 Mn
Dec 31, 2016 133.82 Mn
API Access

Rein Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=RNTX&period=max&api_key=YOUR_API_KEY